Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)
Sanuwave Health (NASDAQ:SNWV), a leading provider of FDA-approved wound care products, reported preliminary Q2 2025 revenues of $10.1-$10.2 million, marking its highest Q2 revenue in company history. This represents a 41-42% increase compared to Q2 2024.
The company has undergone significant commercial expansion, including the appointment of a new head of sales and commercial operations. By July, Sanuwave will have 13 sales representatives covering all national territories, plus a dedicated national accounts manager for larger opportunities. The first half of 2025 showed strong performance with a 50-51% revenue increase compared to the first half of 2024.
Full Q2 2025 results will be released around August 8th, 2025.
Sanuwave Health (NASDAQ:SNWV), un fornitore leader di prodotti per la cura delle ferite approvati dalla FDA, ha riportato ricavi preliminari per il secondo trimestre 2025 compresi tra 10,1 e 10,2 milioni di dollari, segnando il più alto fatturato per un secondo trimestre nella storia dell'azienda. Questo rappresenta un aumento del 41-42% rispetto al secondo trimestre 2024.
L'azienda ha effettuato una significativa espansione commerciale, inclusa la nomina di un nuovo responsabile vendite e operazioni commerciali. Entro luglio, Sanuwave avrà 13 rappresentanti di vendita che copriranno tutti i territori nazionali, oltre a un responsabile dedicato per i grandi clienti nazionali. La prima metà del 2025 ha mostrato una forte performance con un aumento del fatturato del 50-51% rispetto alla prima metà del 2024.
I risultati completi del secondo trimestre 2025 saranno pubblicati intorno al 8 agosto 2025.
Sanuwave Health (NASDAQ:SNWV), un proveedor líder de productos para el cuidado de heridas aprobados por la FDA, informó ingresos preliminares para el segundo trimestre de 2025 de 10.1 a 10.2 millones de dólares, marcando su mayor ingreso en un segundo trimestre en la historia de la compañía. Esto representa un aumento del 41-42% en comparación con el segundo trimestre de 2024.
La empresa ha llevado a cabo una importante expansión comercial, incluyendo el nombramiento de un nuevo jefe de ventas y operaciones comerciales. Para julio, Sanuwave contará con 13 representantes de ventas cubriendo todos los territorios nacionales, además de un gerente de cuentas nacionales dedicado para oportunidades mayores. La primera mitad de 2025 mostró un sólido desempeño con un aumento de ingresos del 50-51% en comparación con la primera mitad de 2024.
Los resultados completos del segundo trimestre de 2025 se publicarán alrededor del 8 de agosto de 2025.
Sanuwave Health (NASDAQ:SNWV)는 FDA 승인 상처 치료 제품의 선도 업체로서, 2025년 2분기 예비 매출이 1,010만에서 1,020만 달러로 회사 역사상 가장 높은 2분기 매출을 기록했다고 발표했습니다. 이는 2024년 2분기 대비 41-42% 증가한 수치입니다.
회사는 영업 및 상업 운영 책임자 신규 임명 등 대대적인 상업 확장을 진행했습니다. 7월까지 Sanuwave는 전국 모든 지역을 커버하는 13명의 영업 대표와 더 큰 기회를 위한 전담 국가 계정 관리자를 보유할 예정입니다. 2025년 상반기는 2024년 상반기 대비 50-51% 매출 증가로 강한 실적을 보였습니다.
2025년 2분기 전체 실적은 2025년 8월 8일경 발표될 예정입니다.
Sanuwave Health (NASDAQ:SNWV), un fournisseur de premier plan de produits de soins des plaies approuvés par la FDA, a annoncé des revenus préliminaires pour le deuxième trimestre 2025 compris entre 10,1 et 10,2 millions de dollars, marquant ainsi le chiffre d'affaires le plus élevé pour un deuxième trimestre dans l'histoire de l'entreprise. Cela représente une augmentation de 41-42% par rapport au deuxième trimestre 2024.
L'entreprise a connu une expansion commerciale significative, incluant la nomination d'un nouveau responsable des ventes et des opérations commerciales. D'ici juillet, Sanuwave disposera de 13 représentants commerciaux couvrant tous les territoires nationaux, ainsi qu'un gestionnaire de comptes nationaux dédié pour les grandes opportunités. Le premier semestre 2025 a montré une forte performance avec une augmentation du chiffre d'affaires de 50-51% par rapport au premier semestre 2024.
Les résultats complets du deuxième trimestre 2025 seront publiés aux alentours du 8 août 2025.
Sanuwave Health (NASDAQ:SNWV), ein führender Anbieter von FDA-zugelassenen Wundversorgungsprodukten, meldete vorläufige Umsätze für das zweite Quartal 2025 in Höhe von 10,1 bis 10,2 Millionen US-Dollar, was den höchsten Umsatz für ein zweites Quartal in der Unternehmensgeschichte darstellt. Dies entspricht einem Anstieg von 41-42% im Vergleich zum zweiten Quartal 2024.
Das Unternehmen hat eine bedeutende kommerzielle Expansion durchlaufen, einschließlich der Ernennung eines neuen Leiters für Vertrieb und kommerzielle Operationen. Bis Juli wird Sanuwave über 13 Vertriebsmitarbeiter verfügen, die alle nationalen Gebiete abdecken, sowie einen dedizierten National Account Manager für größere Geschäftsmöglichkeiten. Das erste Halbjahr 2025 zeigte eine starke Leistung mit einem Umsatzanstieg von 50-51% im Vergleich zur ersten Hälfte 2024.
Die vollständigen Ergebnisse für das zweite Quartal 2025 werden voraussichtlich um den 8. August 2025 veröffentlicht.
- Record Q2 revenue of $10.1-$10.2 million, up 41-42% year-over-year
- First half 2025 revenue growth of 50-51% compared to first half 2024
- Complete national sales territory coverage with 13 sales representatives
- Addition of dedicated national accounts manager for larger market opportunities
- Company in transition period with recent management changes
- Final Q2 results subject to adjustments pending financial close process
Insights
Sanuwave delivers impressive 41-42% revenue growth in Q2, hitting record levels while executing major sales team expansion.
Sanuwave's preliminary Q2 revenue of
What's particularly noteworthy is that Sanuwave achieved this growth during what CEO Morgan Frank described as a "max transition period" where they're essentially rebuilding their commercial infrastructure while maintaining strong sales performance. The company has added a new head of sales, a new head of commercial operations, and is expanding its sales force to 13 representatives by July—achieving full national territory coverage for the first time under the current CEO.
The addition of a dedicated national accounts manager as their "elephant hunter" signals a strategic pivot toward pursuing larger, potentially more profitable enterprise deals that could accelerate growth further. This investment in sales infrastructure during a high-growth period demonstrates management's confidence in their product-market fit and long-term prospects.
While the release doesn't provide specific guidance updates for the remainder of 2025, the fact that Q2 results landed within their previously communicated guidance range suggests reasonable forecasting ability by management. The company's planned August 8th earnings call will likely provide more granular metrics around sales efficiency, customer retention, and updated full-year projections that will help evaluate whether this growth trajectory is sustainable.
Sanuwave is pleased to announce preliminary revenues of
Q2 2025 revenue increased between
First half of 2025 revenue increased 50
EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2025 are expected to be in the range of
“We’re pleased to once more be on guidance and on track for Q2 and for the first half of 2025,” said CEO Morgan Frank. “As we mentioned last quarter, the first half of 2025 has been a transition period for the company as we have added a new head of sales and now a new head of commercial operations. Q2 was really the “max transition” period as we have been staffing up rapidly and will, in July, reach 13 sales people and for the first time in my tenure as CEO have all of our national sales territories covered. We have also added a key national accounts manager to be our dedicated “elephant hunter” in order to better pursue some of the larger opportunities in our market. This has been a period of taking the plane apart and putting it back together all while flying it quite fast, and the team has come through in phenomenal fashion. We’re all very excited about what we’re building here, our pipeline, and the prospects for the year and years ahead. The Company plans to release its full Q2 results on or around August 8th, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
The preliminary revenue results described herein are based on management’s initial analysis of the second quarter ended June 30, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What were Sanuwave Health's (SNWV) preliminary Q2 2025 revenue results?
How much did Sanuwave's revenue grow in the first half of 2025?
When will Sanuwave (SNWV) release its full Q2 2025 earnings report?
How many sales representatives will Sanuwave have by July 2025?
What recent management changes has Sanuwave (SNWV) made in 2025?
